API | polmacoxib

polmacoxib Report issue

Small molecule Experimental

AACT ChEMBL DrugBank PubChem

Active Ingredient History

NOW

Polmacoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat osteoarthritis. It was developed as CG100649 and approved for use in South Korea in February 2015. It inhibits the enzymes carbonic anhydrase and COX-2. A study in healthy volunteers showed drug effects on urinary prostaglandin metabolites for both polmacoxib and celecoxib that suggest a similar cardiovascular risk profile. Further work by this group developed dose-exposure relationships of polmacoxib to guide clinical development strategies. ^Wikipedia

Chemistry

SMILES: CC1(C)OC(=C(C1=O)c2cccc(F)c2)c3ccc(cc3)S(=O)(=O)N
InChIKey: IJWPAFMIFNSIGD-UHFFFAOYSA-N
Mol. Mass: 361.39
ALogP: 2.72 Partition coefficient
ChEMBL Molecule:
polmacoxib

More Chemistry

Pharmacology

Mechanisms of Action:
- Carbonic anhydrase 1 (Homo sapiens) ^UniProt
- Carbonic anhydrase 2 (Homo sapiens) ^UniProt
- Prostaglandin G/H synthase 2 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

cg100649 | polmacoxib

Organizations (8)

Research & Development (8)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)

Healthy Volunteers (Phase 1)

Osteoarthritis (Phase 3)

Osteoarthritis, Hip (Phase 2)

Osteoarthritis, Knee (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 9
# of Trial Organizations: 8

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue